Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peifen Fu

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Medical Oncology|May 7, 2021
Anthracycline-containing <i>versus</i> carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trialHong-Fei Gao, Zhiyong Wu, Ying Lin, et al.
Annals of Translational Medicine|June 24, 2021
Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world studyJun Ma, Huiqiang Huang, Peifen Fu, et al.
Science Advances|October 8, 2025
High-speed photoacoustic and ultrasonic computed tomography of the breast tumor for early diagnosis with enhanced accuracyKeer Huang, Peifen Fu, Hengyue Zhu, et al.
Health and Quality of Life Outcomes|March 25, 2016
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional studyAyong Cao, Jin Zhang, Xiaoan Liu, et al.
BMC Medicine|December 27, 2022
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trialJiong Wu, Zefei Jiang, Zhenzhen Liu, et al.
BMC Cancer|April 21, 2025
Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world studyShukui Qin, Yanxia Shi, Peifen Fu, et al.
Frontiers in Oncology|May 17, 2021
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast CancerJiujun Zhu, Dechuang Jiao, Min Yan, et al.
Iscience|July 18, 2025
Application of sentinel lymph nodes biopsy tracers for breast cancer after neoadjuvant chemotherapy in China: A multicenter, real-world studyFengjiang Qu, Tinghan Jiang, Zhenzhen Liu, et al.
Therapeutic Advances in Medical Oncology|March 9, 2023
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)Heyan Chen, Amina Maimaitiaili, Zhenzhen Liu, et al.
Journal of Cancer Research and Clinical Oncology|May 2, 2023
Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapyAmina Maimaitiaili, Heyan Chen, Peiling Xie, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Medical Oncology|May 7, 2021
Anthracycline-containing <i>versus</i> carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trialHong-Fei Gao, Zhiyong Wu, Ying Lin, et al.
Annals of Translational Medicine|June 24, 2021
Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world studyJun Ma, Huiqiang Huang, Peifen Fu, et al.
Science Advances|October 8, 2025
High-speed photoacoustic and ultrasonic computed tomography of the breast tumor for early diagnosis with enhanced accuracyKeer Huang, Peifen Fu, Hengyue Zhu, et al.
Health and Quality of Life Outcomes|March 25, 2016
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional studyAyong Cao, Jin Zhang, Xiaoan Liu, et al.
BMC Medicine|December 27, 2022
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trialJiong Wu, Zefei Jiang, Zhenzhen Liu, et al.
BMC Cancer|April 21, 2025
Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world studyShukui Qin, Yanxia Shi, Peifen Fu, et al.
Frontiers in Oncology|May 17, 2021
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast CancerJiujun Zhu, Dechuang Jiao, Min Yan, et al.
Iscience|July 18, 2025
Application of sentinel lymph nodes biopsy tracers for breast cancer after neoadjuvant chemotherapy in China: A multicenter, real-world studyFengjiang Qu, Tinghan Jiang, Zhenzhen Liu, et al.
Therapeutic Advances in Medical Oncology|March 9, 2023
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)Heyan Chen, Amina Maimaitiaili, Zhenzhen Liu, et al.
Journal of Cancer Research and Clinical Oncology|May 2, 2023
Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapyAmina Maimaitiaili, Heyan Chen, Peiling Xie, et al.
Pageof 8